GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Portfolio Pulse from Lisa Levin
Several analyst forecasts were released on Wednesday, with price target changes for Rocket Pharmaceuticals, Ultrapar Participações, Casey's General Stores, Kinsale Capital Group, Neurocrine Biosciences, Darden Restaurants, GoDaddy, C.H. Robinson Worldwide, Carpenter Technology, Willis Towers Watson, and Barrick Gold Corporation. The changes ranged from cuts to increases, with varying impacts on pre-market trading.
September 13, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs slashed Ultrapar Participações' price target from $4.5 to $4 and downgraded the stock from Buy to Neutral. The company's shares gained 1.3% on Tuesday.
The price target cut and downgrade by Goldman Sachs could potentially impact the stock negatively in the short term as it indicates a less optimistic outlook for the company.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
BMO Capital raised the price target for Casey's General Stores from $270 to $290, maintaining an Outperform rating. The company's shares fell 0.1% in pre-market trading.
Despite the price target increase by BMO Capital, the company's shares fell slightly in pre-market trading. This suggests a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Benchmark cut C.H. Robinson Worldwide's price target from $108 to $100, maintaining a Buy rating. The company's shares rose 0.1% in pre-market trading.
Despite the price target cut by Benchmark, the company's shares rose slightly in pre-market trading. This suggests a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
BMO Capital cut Darden Restaurants' price target from $167 to $160, maintaining a Market Perform rating. The company's shares rose 1.1% on Tuesday.
Despite the price target cut by BMO Capital, the company's shares rose slightly. This suggests a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
BMO Capital boosted Barrick Gold Corporation's price target from $29 to $30, maintaining an Outperform rating. The company's shares fell 0.2% in pre-market trading.
Despite the price target increase by BMO Capital, the company's shares fell slightly in pre-market trading. This suggests a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Piper Sandler cut Willis Towers Watson's price target from $270 to $265, maintaining an Overweight rating. The company's shares rose 0.5% on Tuesday.
Despite the price target cut by Piper Sandler, the company's shares rose slightly. This suggests a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Benchmark increased the price target for Carpenter Technology from $65 to $100, maintaining a Buy rating. The company's shares rose 1.1% in pre-market trading.
The price target increase by Benchmark had a positive impact on the stock, with shares rising slightly in pre-market trading. This suggests a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
B. Riley Securities raised GoDaddy's price target from $102 to $107, maintaining a Buy rating. The company's shares rose 1.3% on Tuesday.
The price target increase by B. Riley Securities had a positive impact on the stock, with shares rising slightly. This suggests a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
BMO Capital boosted the price target for Kinsale Capital Group from $415 to $450, maintaining an Outperform rating. The company's shares rose 0.2% on Tuesday.
The price target increase by BMO Capital had a positive impact on the stock, with shares rising slightly. This suggests a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
BMO Capital lifted Neurocrine Biosciences' price target from $100 to $111, maintaining a Market Perform rating. The company's shares gained 6.8% on Tuesday.
The price target increase by BMO Capital had a positive impact on the stock, with shares gaining significantly. This suggests a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Needham cut the price target for Rocket Pharmaceuticals from $60 to $53, maintaining a Buy rating. The company's shares rose 24.3% in pre-market trading.
The price target cut by Needham, despite being a negative adjustment, did not negatively impact the stock as it rose significantly in pre-market trading. This suggests investor confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100